title: Low fitness cost of the multidrug resistance gene cfr.
abstract: The recently described rRNA methyltransferase Cfr that methylates the conserved 23S rRNA residue A2503, located in a functionally critical region of the ribosome, confers resistance to an array of ribosomal antibiotics, including linezolid. A number of reports of linezolid-resistant cfr-positive clinical strains indicate the possible rapid spread of this resistance mechanism. Since the rate of dissemination and the efficiency of maintenance of a resistance gene depend on the fitness cost associated with its acquisition, we investigated the fitness cost of cfr expression in a laboratory Staphylococcus aureus strain. We found that acquisition of the cfr gene does not produce any appreciable reduction in the cell growth rate. Only in a cogrowth competition experiment was some loss of fitness observed because Cfr-expressing cells slowly lose to the cfr-negative control strain. Interestingly, cells expressing wild-type and catalytically inactive Cfr had very similar growth characteristics, indicating that the slight fitness cost associated with cfr acquisition stems from expression of the Cfr polypeptide rather than from the modification of the conserved rRNA residue. In some clinical isolates, cfr is coexpressed with the erm gene, which encodes a methyltransferase targeting another 23S rRNA residue, A2058. Dimethylation of A2058 by Erm notably increases the fitness cost associated with the Cfr-mediated methylation of A2503. The generally low fitness cost of cfr acquisition observed in our experiments with the laboratory S. aureus strain offers a microbiological explanation for the apparent spread of the cfr gene among pathogens.
authors.affiliation: Center for Pharmaceutical Biotechnology, University of Illinois, 900 S. Ashland Ave., Chicago, IL 60607, USA.
authors.forename: Jacqueline M
authors.initials: JM
authors.lastname: LaMarre
authors.forename: Jeffrey B
authors.initials: JB
authors.lastname: Locke
authors.forename: Karen J
authors.initials: KJ
authors.lastname: Shaw
authors.forename: Alexander S
authors.initials: AS
authors.lastname: Mankin
mesh_terms: D000081:Acetamides / Q000494:pharmacology*; D001426:Bacterial Proteins / Q000235:genetics* / Q000378:metabolism*; D024901:Drug Resistance, Multiple, Bacterial / Q000235:genetics*; D006801:Humans; D000069349:Linezolid; D008780:Methyltransferases / Q000235:genetics / Q000378:metabolism; D008826:Microbial Sensitivity Tests; D023303:Oxazolidinones / Q000494:pharmacology*; D012335:RNA, Ribosomal / Q000235:genetics* / Q000378:metabolism; D012338:RNA, Ribosomal, 23S / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000235:genetics* / Q000254:growth & development / Q000378:metabolism
chemical_list: D000081:Acetamides; D001426:Bacterial Proteins; C539943:CFR protein, Staphylococcus aureus; D023303:Oxazolidinones; D012335:RNA, Ribosomal; D012338:RNA, Ribosomal, 23S; D008780:Methyltransferases; D000069349:Linezolid